- Home
- LIN vs AZN Comparison
LIN vs AZN Comparison
Compare LIN & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LIN | AZN |
|---|---|---|
| Founded | 1879 | 1992 |
| Country | United Kingdom | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.1B | 250.7B |
| IPO Year | 2017 | 1995 |
Fundamental Metrics
Financial Performance| Metric | LIN | AZN |
|---|---|---|
| Price | $497.22 | $165.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 29 | 12 |
| Target Price | ★ $544.15 | $207.16 |
| AVG Volume (30 Days) | 2.0M | ★ 2.4M |
| Earning Date | 10-29-2026 | 10-30-2026 |
| Dividend Yield | 1.30% | ★ 1.94% |
| EPS Growth | ★ 7.27 | N/A |
| EPS | ★ 8.13 | N/A |
| Revenue | ★ $33,986,000,000.00 | N/A |
| Revenue This Year | $6.90 | $7.93 |
| Revenue Next Year | $4.87 | $6.26 |
| P/E Ratio | $60.67 | ★ $31.91 |
| Revenue Growth | ★ 2.97 | N/A |
| 52 Week Low | $387.78 | $80.48 |
| 52 Week High | $548.20 | $212.71 |
Technical Indicators
Market Signals| Indicator | LIN | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 67.34 | 55.52 |
| Support Level | $487.51 | $164.06 |
| Resistance Level | $509.77 | $168.42 |
| Average True Range (ATR) | 7.06 | 3.12 |
| MACD | 2.57 | 0.65 |
| Stochastic Oscillator | 88.18 | 70.15 |
Price Performance
Historical ComparisonAbout LIN Linde plc
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $34 billion in revenue in 2025.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.